Cardinal Health extends its distribution agreement with CVS Health through 2032
On Oct. 1, 2026, Cardinal Health signed a binding letter of intent to extend its pharmaceutical distribution agreement with CVS Health to June 30, 2032, while reaffirming its fiscal 2027 non‑GAAP earnings per share (EPS) outlook of $12.40‑$12.60.
Key points
- Cardinal Health, Inc. announced the signing of a binding letter of intent that extends its existing pharmaceutical distribution agreement with CVS Health to June 30, 2032.
- The deal continues the current scope of distribution services under unchanged terms, preserving existing pricing and procedures through the end of June 2032.
- In fiscal 2026, the company reported strong execution and broad‑based performance, and noted active board oversight of growth priorities, investments and capital management.
What happened
Cardinal Health, Inc. announced the signing of a binding letter of intent that extends its existing pharmaceutical distribution agreement with CVS Health to June 30, 2032.
Deal terms
The deal continues the current scope of distribution services under unchanged terms, preserving existing pricing and procedures through the end of June 2032.
Context
In fiscal 2026, the company reported strong execution and broad‑based performance, and noted active board oversight of growth priorities, investments and capital management.
What to watch
Investors should watch for the signing of a final agreement with CVS Health and for fiscal 2027 earnings per share (EPS) results to see if the company meets the reaffirmed $12.40‑$12.60 forecast.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Cardinal Health
A notification in your browser or on your phone when we publish about Cardinal Health. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
